nafamostat has been researched along with Endothelioma, Vascular in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saito, M | 1 |
| Gunji, Y | 1 |
| Kashii, Y | 1 |
| Odaka, J | 1 |
| Yamauchi, T | 1 |
| Kanai, N | 1 |
| Momoi, MY | 1 |
1 other study available for nafamostat and Endothelioma, Vascular
| Article | Year |
|---|---|
Refractory kaposiform hemangioendothelioma that expressed vascular endothelial growth factor receptor (VEGFR)-2 and VEGFR-3: a case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Benzamidine | 2009 |